Design Therapeutics Inc
Design Therapeutics Inc (DSGN) Straddle
DSGN straddle scan found 27 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 67.8%.
Read more
Trading a DSGN straddle lets you take a pure volatility position on Design Therapeutics Inc without committing to a direction. Design Therapeutics Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate DSGN straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on DSGN profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Design Therapeutics Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the DSGN straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs.
It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the DSGN straddle is the cleanest expression of that view. Our scanner prices every DSGN straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a DSGN straddle into a catalyst or short a DSGN straddle to harvest decay, the options straddle setups that matter are all in one place.
| Apr 16, 2027 | 18.00 | $9.35 | 211 | 54% | 67.8% | $27.35 | $8.65 | 0 |
| Apr 16, 2027 | 16.00 | $8.00 | 211 | 54% | 67.4% | $24.00 | $8.00 | 0 |
| Apr 16, 2027 | 21.00 | $11.85 | 211 | 54% | 67.0% | $32.85 | $9.15 | 0 |
| Apr 16, 2027 | 19.00 | $10.30 | 211 | 54% | 66.9% | $29.30 | $8.70 | 0 |
| Apr 16, 2027 | 17.00 | $8.85 | 211 | 54% | 66.7% | $25.85 | $8.15 | 0 |
| Apr 16, 2027 | 20.00 | $11.30 | 211 | 54% | 65.9% | $31.30 | $8.70 | 0 |
| Apr 16, 2027 | 14.00 | $6.98 | 211 | 54% | 65.6% | $20.98 | $7.03 | 0 |
| Apr 16, 2027 | 13.00 | $6.55 | 211 | 54% | 64.1% | $19.55 | $6.45 | 0 |
| Jan 15, 2027 | 17.00 | $7.65 | 120 | 54% | 62.3% | $24.65 | $9.35 | 0 |
| Apr 16, 2027 | 15.00 | $8.20 | 211 | 54% | 62.2% | $23.20 | $6.80 | 0 |
As of September 17, 2026
Find the right straddle before volatility moves
Track DSGN straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.
Start your 14-day free trial→